In the city of dreams, one family is trapped in a slow, waking nightmare. This isn’t a sudden story of loss; it’s a story of ...

Company receives expanded access protocol authorization from the U.S. Food and Drug Administration (FDA) for troculeucel granted to treat patients with known diagnoses of multiple neurodegenerative ...

John Maskill, 89, decided to walk the Cinder Track after losing his wife to Progressive Supranuclear Palsy (PSP) in March.

Amylyx is a high-risk biotech targeting rare diseases with strong cash reserves. Key trials soon may drive a 40% stock upside.